At Cellen Therapeutics we are inspired by the stories of the patients we help

Cellen Therapeutics is an independent, UK-based company working with industry partners to ensure patients receive products compliant with EU GACP, EU GMP and EU GDP standards.

Meet the Team

Eric Bystrom

Chief Executive Officer

Dr Benjamin Viaris de Lesegno MD, MSc

Chief Medical Officer & NHS Doctor

Dr Haggai Sharon MD, PhD

Chairman of Clinical Board & NHS Doctor

Project Twenty21

Cellen is one of the founding partners of the leading Medical Cannabis Project Twenty21, overseen by DrugScience.

Twenty21

Project Twenty21 will be the largest European observational registry of patients taking prescribed Cannabis-based Medicinal Products.

 

We will be aiming to enrol 20,000 UK patients over the next 2 years to understand safety and efficacy of Medical Cannabis. As a UK-based, independent company, we are thrilled at Cellen to be continuing our mission of improving the health of people living with chronic conditions

“As a science-led company, Cellen is proud to participate in Europe’s largest Medical Cannabis research project, to further our understanding of the efficacy of cannabis-based medical products and provide a substantial evidence base which we hope will shape the future of Medical Cannabis treatment in the UK.”

– Dr Benjamin Viaris de Lesegno MD MSc

Co-Founder & Chief Medical Officer of Cellen

Cannon Place

78 Cannon Street

London

United Kingdom

EC4N 6AF

020 4522 8805

  • White Facebook Icon
  • White Twitter Icon
  • White Instagram Icon
  • White LinkedIn Icon

© 2020 Cellen™ All rights reserved